middle.news
Noxopharm clears first-in-human safety hurdle as SOF-SKN advances
10:32am on Friday 16th of October, 2026 AEDT
•
Biotechnology
Read Story
Noxopharm clears first-in-human safety hurdle as SOF-SKN advances
10:32am on Friday 16th of October, 2026 AEDT
Key Points
SOF-SKN reported safe and well tolerated in healthy volunteers
Extension study planned in cutaneous lupus patients
Annual loss narrowed to A$4.46 million
Operating cash outflow fell to A$2.71 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE